Chuen Yan Cheng

Chuen Yan Cheng (Chinese: 鄭泉恩) is a Senior Scientist for the Population Council's Center for Biomedical Research. He is most well known as the inventor of the non-steroid male contraceptive drug—Adjudin,^[1][2][3][4] which is the first male contraceptive drug on the market now finished clinical trials showing no side effects.^[5][6]

Prof Chuen Yan Cheng
Born	(1954-06-18) June 18, 1954 (age 71) Hong Kong, China
Nationality	American
Alma mater	Chinese University of Hong Kong (B.Sc.) University of Newcastle, Australia (Ph.D.)
Known for	Male contraceptive drug
Awards	Richard E. Weizman Memorial Award Best Scientific Paper Award
Scientific career
Fields	Biochemistry
Institutions	Rockefeller University

Career

He graduated from the Chinese University of Hong Kong with a B.Sc. in 1977, and obtained his Ph.D. in biochemistry and cell biology at the University of Newcastle, Australia, in 1981. He came to New York as a Population Council post-doctoral trainee in 1981, studying in the laboratory of Drs. Wayne Bardin, Neal Musto, and Glen Gunsalus and was appointed as a research investigator in December 1982.

Cheng's research focuses on the development of a novel contraceptive for human males. These studies currently are supported by grants from the National Institutes of Health, the CONRAD Program, and the Andrew Mellon Foundation.